How much is CGIX?
How much is CGIX?
CGIX Price/Volume Stats
| Current price | $4.61 | 52-week high |
|---|---|---|
| Day low | $4.30 | Volume |
| Day high | $4.69 | Avg. volume |
| 50-day MA | $5.46 | Dividend yield |
| 200-day MA | $3.87 | Market Cap |
What happened to CGIX?
The business combination of Cancer Genetics, Inc. (CGIX) and StemoniX was completed and became effective today, Tuesday, March 30, 2021. Following the completion of the business combination, the company will undergo name, symbol, and CUSIP number changes. These actions will become effective on March 31, 2021.
Who is CGIX merging with?
StemoniX, Inc.
(the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. (“StemoniX”).
Will CGIX go up?
Will Cancer Genetics stock price grow / rise / go up? Yes. The CGIX stock price can go up from 4.640 USD to 6.121 USD in one year.
Is CGIX a good stock?
7 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for ChemoCentryx in the last twelve months. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should “buy” ChemoCentryx stock.
What is CGIX?
CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. StemoniX will operate as a wholly-owned subsidiary of the Company.
What is CGIX in stock market?
Cancer Genetics Inc (CGIX)
Is Ccxi a good stock?
Will Ccxi bounce back?
Shares of ChemoCentryx were soaring in 2020 until an FDA advisory committee vote pulled the rug out from under its stock price in May. After giving up around 41% of its value this year, an upcoming clinical trial readout could allow shares of this biotech to bounce right back.
Are cancers hereditary?
About 5 to 10 percent of cancers are thought to be hereditary. In these cases, an individual inherits a copy of a growth control gene with a mutation from one parent, and a working copy of the same gene from the other parent.
Should I sell ChemoCentryx?
7 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for ChemoCentryx in the last year. The consensus among Wall Street analysts is that investors should “buy” ChemoCentryx stock.
